LPTX · Leap Therapeutics Inc

-

Please sign in to comment on LPTX

1 Comment

Admin

4 years ago

Leap Therapeutics, Inc is currently in a long term downtrend where the price is trading 21.6% below its 200 day moving average.

From a valuation standpoint, the stock is 94.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 75.1.

Leap Therapeutics, Inc's total revenue rose by inf% to $375K since the same quarter in the previous year.

Its net income has increased by 16.1% to $-7M since the same quarter in the previous year.

Finally, its free cash flow grew by 0.1% to $-6M since the same quarter in the previous year.

Based on the above factors, Leap Therapeutics, Inc gets an overall score of 4/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US52187K1016

Beta	0.21
Market Cap	16M
PE Ratio	None
Target Price	3
Dividend Yield	None

ABOUT

Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX · Leap Therapeutics Inc

-

Leap Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Leap Therapeutics Inc using a moving average strategy